Related Experiment Video
Updated: Apr 1, 2026
Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
VEGF-A and the NLRP3 Inflammasome in Age-Related Macular Degeneration
1Department of Dermatology, Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, 02129, Charlestown, MA, USA. amarneros@mgh.harvard.edu.
Abstract:
The pathomechanisms that lead to age-related macular degeneration (AMD) are only partially understood. The NLRP3 inflammasome has been shown to be activated in the retinal pigment epithelium (RPE) in eyes with AMD. However, it is not known whether inflammasome activation is a cause or consequence of pathologic changes in AMD. A roadblock to defining the role of inflammasome activation and pathways that regulate it for AMD has been the lack of a mouse model that forms AMD-like pathologies in an age-dependent manner in which the role of the inflammasome can be investigated using genetic studies. We have recently identified such a mouse model, in which increased VEGF-A levels result in early degenerative changes of the RPE, followed by cardinal features of both nonexudative and neovascular AMD. Importantly, higher VEGF-A levels lead to increased oxidative damage and a sub-retinal inflammatory infiltrate that are associated with NLRP3 inflammasome activation in the RPE. Targeting the NLRP3 inflammasome inhibited AMD-like pathologies in these mice. These findings suggest that inhibiting the NLRP3 inflammasome or pathways that regulate it may provide novel therapeutic approaches for the treatment of both forms of AMD.
Insights
Researchers identified a mouse model for age-related macular degeneration (AMD). Targeting the NLRP3 inflammasome inhibited AMD pathologies, suggesting it as a potential therapeutic target for AMD treatment.
Area of Science:
- Ophthalmology
- Immunology
- Genetics
Background:
- Age-related macular degeneration (AMD) pathogenesis is not fully understood.
- NLRP3 inflammasome activation occurs in AMD, but its causal role is unclear.
- A suitable mouse model is needed to study inflammasome involvement in AMD.
Purpose of the Study:
- To investigate the role of NLRP3 inflammasome in AMD pathogenesis.
- To characterize a novel mouse model exhibiting age-dependent AMD-like pathologies.
- To evaluate the therapeutic potential of targeting the NLRP3 inflammasome in AMD.
Main Methods:
- Developed a mouse model with increased VEGF-A levels, leading to RPE degeneration.
- Observed age-dependent development of nonexudative and neovascular AMD features.
- Assessed oxidative damage, inflammatory infiltrate, and NLRP3 inflammasome activation.
- Administered NLRP3 inflammasome inhibitors to evaluate therapeutic effects.
Main Results:
- The mouse model recapitulated key features of AMD, including RPE changes and inflammation.
- Increased VEGF-A correlated with oxidative stress and NLRP3 inflammasome activation.
- Inhibition of NLRP3 inflammasome significantly reduced AMD-like pathologies.
- VEGF-A-driven AMD progression involves oxidative damage and NLRP3 inflammasome activation.
Conclusions:
- NLRP3 inflammasome activation is a key driver of AMD-like pathologies in this model.
- Targeting the NLRP3 inflammasome offers a promising therapeutic strategy for AMD.
- This mouse model is valuable for studying AMD mechanisms and testing interventions.
